Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why NextCure Crashed Today

By Maxx Chatsko - Nov 11, 2019 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Highly anticipated clinical trial results didn't continue a promising trend from a smaller number of patients.

What happened

Shares of NextCure ( NXTC 2.94% ) fell as much as 55.3% today after the company presented updated data for NC318 over the weekend. The expanded results aren't as rosy as the preliminary data reported earlier this month that caused the small-cap stock to erupt for a daily gain of more than 200%.

But great results from a low number of patients mean relatively little until they're replicated in larger populations. That said, it's a little difficult to draw too many conclusions one way or the other for the ongoing phase 1/2 trial of NC318. It was evaluated in many tumor types, with many doses, and with many unique genetic profiles of the individuals involved. NextCure will need results with fewer variables (such as settling on a dose or two) and from a much larger patient population before investors know if the company's novel approach to discovering immunotherapy drug candidates can live up to the hype.

As of 11:23 a.m. EST, the stock had settled to a 51.6% loss.

A pink arrow crashing through the x-axis of a chart.

Image source: Getty Images.

So what

In the preliminary data reported in the beginning of November, 5 of the first 7 non-small cell lung cancer (NSCLC) patients treated with NC318 in the phase 1/2 trial achieved a response or stopped their cancers from progressing as of the cutoff date. That included one complete response (read: no signs of cancer), one partial response (read: tumor shrinkage), and three patients with stable disease. That translated to a disease control rate (DCR) of 71%.

In the updated data reported over the weekend at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), NextCure presented results from 10 patients with NSCLC who were evaluable at the new cutoff date. No new responses or signs of stable disease were reported, and four patients dropped out of the study. Three more have yet to reach the eight-week check-in, which means they were not evaluable and were not included in the most recent data.

The results are also a little messy. The patient who achieved a complete response took an 8 mg dose of NC318 every two weeks, while the patient who achieved a partial response took 400 mg every two weeks. Three patients with stable disease are taking an 80 mg dose every two weeks, and the other is on the 400 mg dose.

NextCure also evaluated its lead drug candidate beyond NSCLC, studying 15 unique tumor types in all as part of the study. There were 14 patients with stable disease in all, although only 15 remain in the phase 1 trial.

Now what

Despite today's drop, shares of NextCure have gained 56% in the last month. But today's news is just the latest reminder that investors shouldn't get too carried away when it comes to clinical results from a very small number of patients. Oftentimes, the numbers simply don't hold up. That said, the ongoing phase 1/2 trial will progress to a larger phase 2 study, which will provide more valuable data for investors to pore over. It should be completed by the end of 2020 or early 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NextCure, Inc. Stock Quote
NextCure, Inc.
$6.30 (2.94%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.